APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability,
efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with
relapsed/refractory (RR) multiple myeloma (MM). The study consists of dose escalation and
dose expansion phases. The study consists of will start with 2 arms noted below, both arms
are independent